Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 36

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 36
---
ner qualifies as an “audit committee financial expert” as defined by Item 407(d)(5)(ii) of Regulation S-K.

In 2024, the Audit Committee met five times.

#### Compensation Committee
Our Compensation Committee is responsible for assisting the Board in the discharge of its responsibilities relating to the compensation of our executive officers. In fulfilling its purpose, our Compensation Committee has the following principal duties:

• annually reviewing and approving corporate goals and objectives relevant to Chief Executive Officer compensation;

• reviewing and approving, or making recommendations to our Board with respect to, the compensation of our Chief Executive Officer and other executive officers;

• overseeing an evaluation of our senior executives;

• administering our cash and equity incentive plans;

• reviewing and making recommendations to our Board with respect to director compensation;

• reviewing and discussing annually with management our “Compensation Discussion and Analysis”; and

• preparing the annual compensation committee report, if required by SEC rules.

The Compensation Committee has the authority to retain or obtain the advice of compensation consultants, legal counsel and other advisors to assist it in carrying out its responsibilities.

The Compensation Committee may delegate its authority under its charter to one or more subcommittees as it deems appropriate from time to time as further described in its charter, which is available on the “Corporate Governance” section of the “Investors” page of our website at www.cartesiantherapeutics.com. The Compensation Committee may also delegate to an officer the authority to grant equity awards to certain employees, as further described in its charter and subject to the terms of our equity plans.

In 2024, the Compensation Committee engaged Compensia, Inc. (“Compensia”), a compensation consulting firm, to assess and make recommendations with respect to the amount and types of compensation to provide our executives and directors. Compensia reported directly to the Compensation Committee; however, our Chief Executive Officer consulted with Compensia with respect to its assessments of the compensation of executive officers other than the Chief Executive Officer. The Compensation Committee reviewed compensation assessments provided by Compensia comparing our compensation to that of a group of peer companies within our industry and met with Compensia to discuss compensation of our executive officers and our Board, including the Chief Executive Officer, and to receive input and advice. The Compensation Committee has considered the adviser independence factors required under SEC rules as they relate to Compensia and does not believe Compensia’s prior work in 2023 or work in 2024 raised a conflict of interest.

The Compensation Committee uses competitive compensation data from an annual total compensation study